Sort
10,766 grants matching “checkpoint inhibitor”
Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity
$161,230Shweta Joshi · University Of California, San Diego · K22 · FY2020 · CA
Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity
$161,230Shweta Joshi · University Of California, San Diego · K22 · FY2022 · CA
Regulation of Genomic Instability in Early Breast Cancer
$160,948Thea D Tlsty · University Of California, San Francisco · R01 · FY2006 · CA
Employing Novel Primary Mouse Models of Head and Neck Cancer to Overcome Chemoradiation Resistance
$160,812Yvonne Marie Mowery · Duke University · K08 · FY2022 · DE
Employing Novel Primary Mouse Models of Head and Neck Cancer to Overcome Chemoradiation Resistance
$160,812Yvonne Marie Mowery · University Of Pittsburgh At Pittsburgh · K08 · FY2024 · DE
Employing Novel Primary Mouse Models of Head and Neck Cancer to Overcome Chemoradiation Resistance
$160,812Yvonne Marie Mowery · University Of Pittsburgh At Pittsburgh · K08 · FY2023 · DE
Checkpoints of TNF Gene Regulation
$160,764Anne Goldfeld · Immune Disease Institute, Inc. · R01 · FY2012 · GM
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment
$160,652Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · SB1 · FY2024 · CA
POTENTIATION OF TAXANE ACTIVITY BY MEK/MAPK INHIBITORS
$160,466Virginia Commonwealth University · R01 · FY2001 · CA
Structural studies of molecular cancer targets and drug development
$160,204David S Waugh · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy
$160,114Jin-Ming Yang · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2018 · CA
The role of the PI3K pathway in immune resistance
$160,000Patrick Hwu · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA
Robust Predictor of Breast Cancer Risk
$160,000Harry Ostrer · Morgan And Mendel Genomics, Inc. · R42 · FY2022 · CA
The role of the PI3K pathway in immune resistance
$160,000Patrick Hwu · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · CA
COMBINATION OF CHECKPOINT INHIBITORS
$160,000Sanjeev Redkar · Apollomics, Inc. · R43 · FY2018 · CA
Centers for Cancer Systems Therapeutics (CaST)
$160,000Andrea Califano · Columbia University Health Sciences · U54 · FY2016 · CA
Elucidating genetics of response to immune checkpoint blockade in lung cancer
$159,998Naiyer A Rizvi · Columbia University Health Sciences · R01 · FY2018 · CA
Elucidating genetics of response to immune checkpoint blockade in lung cancer
$159,998Naiyer A Rizvi · Columbia University Health Sciences · R01 · FY2017 · CA
Developing Therapy for the Treatment of Cholangiocarcinoma
$159,863Karina J Yoon · University Of Alabama At Birmingham · R21 · FY2017 · CA
Wwox and Fhit loss and the DNA damage response in breast cancer subtypes
$159,760Kay Huebner · Ohio State University · R01 · FY2012 · CA
Wwox and Fhit loss and the DNA damage response in breast cancer subtypes
$159,760Kay Huebner · Ohio State University · R01 · FY2011 · CA
Regulation of Colon Cancer by AIM2
$159,549Justin Ethan Wilson · University Of Arizona · K22 · FY2019 · CA
Regulation of Colon Cancer by AIM2
$159,549Justin Ethan Wilson · University Of Arizona · K22 · FY2020 · CA
Remotely controlled listerial bactodrones for cancer immunotherapy
$159,391Mark Gomelsky · University Of Wyoming · R21 · FY2022 · CA
Defining immune footprint in tumor microenvironment following high salt synergized inflammatory cytokine mediated breast cancer progression
$159,183Venkataswarup Tiriveedhi · Tennessee State University · U54 · FY2018 · CA